Healthwell Acquisition Corp. I - Class A
News
Healthwell Acquisition Corp. I Announces Cancellation of Special Stockholder Meeting and its Intention to Liquidate
Business Wire Healthwell Acquisition Corp. I (Healthwell) (Nasdaq: HWEL) announced today that (i) its previously announced special meeting of stockholders that was scheduled for December 4, 2023 has been...\n more…
Healthwell Acquisition Corp. I Announces Termination of Business Combination with Starton Therapeutics, Inc.
Business Wire Healthwell Acquisition Corp. I (Healthwell) (Nasdaq: HWEL) announced today that its previously announced Business Combination Agreement in connection with its planned business combination with...\n more…
Healthwell Acquisition Corp. I Announces Postponement of the Special Meeting of Stockholders to Approve the Proposed Business Combination with Starton Therapeutics, Inc. and Related Transacti
Business Wire Healthwell Acquisition Corp. I (Healthwell, HWEL or the Company) (NASDAQ: HWEL) announced today that it has postponed until further announcement the date of the special meeting of the Companys...\n more…
Healthwell Acquisition Corp. I Announces New Meeting Date for the Special Meeting of Stockholders to Approve Proposed Business Combination With Starton Therapeutics, Inc. and Related Transact
Business Wire Healthwell Acquisition Corp. I (Healthwell, HWEL or the Company) (NASDAQ: HWEL) announced today that it has postponed the date of the special meeting of the Companys stockholders (the Meeting) to...\n more…
Starton Therapeutics Contracts Global Clinical Research Organization to Conduct STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma
Business Wire Starton Therapeutics Inc. (Starton or the Company), a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, today entered into a definitive agreement to conduct its Phase 1b trial in multiple myeloma with a global...\n more…
Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma
Business Wire Starton Therapeutics Inc. (Starton or the Company), a clinical stage biotechnology company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, today provided updates on its Phase 1b STAR-LLD clinical trial of its investigational continuous delivery...\n more…